BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34325056)

  • 1. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
    Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
    J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
    Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
    EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary.
    Shen Y; Chu Q; Yin X; He Y; Bai P; Wang Y; Fang W; Timko MP; Fan L; Jiang W
    Brief Bioinform; 2021 Mar; 22(2):2106-2118. PubMed ID: 32266390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
    Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
    ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A second-generation microRNA-based assay for diagnosing tumor tissue origin.
    Meiri E; Mueller WC; Rosenwald S; Zepeniuk M; Klinke E; Edmonston TB; Werner M; Lass U; Barshack I; Feinmesser M; Huszar M; Fogt F; Ashkenazi K; Sanden M; Goren E; Dromi N; Zion O; Burnstein I; Chajut A; Spector Y; Aharonov R
    Oncologist; 2012; 17(6):801-12. PubMed ID: 22618571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Clinical Validation of a 90-Gene Expression Assay for Identifying Tumor Tissue Origin.
    Ye Q; Wang Q; Qi P; Chen J; Sun Y; Jin S; Ren W; Chen C; Liu M; Xu M; Ji G; Yang J; Nie L; Xu Q; Huang D; Du X; Zhou X
    J Mol Diagn; 2020 Sep; 22(9):1139-1150. PubMed ID: 32610162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing unknown tumor origins with a biological-pathway-based transformer model.
    Xie J; Chen Y; Luo S; Yang W; Lin Y; Wang L; Ding X; Tong M; Yu R
    Cell Rep Methods; 2024 Jun; 4(6):100797. PubMed ID: 38889685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
    Rassy E; Pavlidis N
    Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
    Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
    J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
    Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
    Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
    Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
    Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep learning-based cancer survival prognosis from RNA-seq data: approaches and evaluations.
    Huang Z; Johnson TS; Han Z; Helm B; Cao S; Zhang C; Salama P; Rizkalla M; Yu CY; Cheng J; Xiang S; Zhan X; Zhang J; Huang K
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):41. PubMed ID: 32241264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling.
    Varadhachary G
    Clin Cancer Res; 2013 Aug; 19(15):4027-33. PubMed ID: 23519898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin.
    Ferracin M; Pedriali M; Veronese A; Zagatti B; Gafà R; Magri E; Lunardi M; Munerato G; Querzoli G; Maestri I; Ulazzi L; Nenci I; Croce CM; Lanza G; Querzoli P; Negrini M
    J Pathol; 2011 Sep; 225(1):43-53. PubMed ID: 21630269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the site of origin of tumors by a gene expression signature derived from normal tissues.
    Staub E; Buhr HJ; Gröne J
    Oncogene; 2010 Aug; 29(31):4485-92. PubMed ID: 20514016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
    Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
    J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.